信达生物高剂量减重药上市申请获国家药监局受理

Core Viewpoint - The company, Innovent Biologics, announced that its GCG/GLP-1 dual receptor agonist, Masitide, has received acceptance for a marketing application from the National Medical Products Administration (NMPA) in China for long-term weight control in adults with moderate to severe obesity [1] Group 1 - The marketing application for Masitide is specifically for a high dosage of 9mg [1] - The target patient population for this drug includes adults suffering from moderate to severe obesity [1] - The acceptance by NMPA's Center for Drug Evaluation (CDE) marks a significant step in the drug's commercialization process in China [1]